Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMA9FKY)

• Drug Name: AG140699 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Phase 2	[1]

• Therapeutic Class: Anticancer Agents
• Cross-matching ID: TTD Drug ID: DMA9FKY

Molecule-Related Drug Atlas

Drug(s) Targeting Poly [ADP-ribose] polymerase 1 (PARP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nicotinamide	DMUPE07	Acne vulgaris	ED80	Approved	[3]
KU-0058948	DMSA4HZ	Ovarian cancer	2C73	Approved	[4]
Niraparib Tosylate	DMLPSWQ	Fallopian tube cancer	2C74	Approved	[5]
CC-486	DMTNQB0	Acute myeloid leukaemia	2A60	Phase 3	[6]
Nicaraven	DMFBNA3	Cerebrovascular disease	8B2Z	Phase 3	[7]
PMID27841036-Compound-37	DM0OVZ2	Ovarian cancer	2C73	Phase 2	[8]
Stenoparib	DMKVBL8	Ovarian cancer	2C73	Phase 2	[9]
AZD5305	DMW9R1C	Prostate cancer	2C82.0	Phase 2	[10]
AMXI 5001	DMR9H6B	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[11]
NMS-03305293	DM2XIRW	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Poly [ADP-ribose] polymerase 1 (PARP1)	TTVDSZ0	PARP1_HUMAN	Inhibitor	[2]

References

• [1] Critical Care Nephrology, Claudio Ronco,Rinaldo Bellomo,John A. Kellum. Page(444).
• [2] Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005 May;4(5):421-40.
• [3] beta-1,2,3-Triazolyl-nucleosides as nicotinamide riboside mimics. Nucleosides Nucleotides Nucleic Acids. 2009 Mar;28(3):238-59.
• [4] Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3. J Med Chem. 2009 May 14;52(9):3108-11.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2003 Jan 16;46(2):210-3.
• [7] Inhibition of poly (ADP-ribose) polymerase as a protective effect of nicaraven in ionizing radiation- and ara-C-induced cell death. Anticancer Res. 2006 Sep-Oct;26(5A):3421-7.
• [8] PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
• [9] Clinical pipeline report, company report or official report of Allarity Therapeutics.
• [10] Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper. Clin Cancer Res. 2022 Nov 1;28(21):4724-4736.
• [11] AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers. Am J Cancer Res. 2020 Aug 1;10(8):2649-2676.
• [12] NMS-P293, a PARP-1 selective inhibitor with no trapping activity and high CNS penetration, possesses potent in vivo efficacy and represents a novel therapeutic option for brain localized metastases and glioblastoma. Cancer Res 2018;78(13 Suppl):Abstract nr 4843.